| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Lexicon Genetics, Inc. |
| 4000 Research Forest Drive, The Woodlands, TX 77381 * (281) 364-0100 |
| Business Description | The company is using technology that we invented to define the functions of genes for drug discovery. This technology, which we refer to as gene trapping, alters the DNA of genes in a special variety of mouse cells, called embryonic stem (ES) cells, which can be cloned and used to generate mice. |
| Offering Information Company has | |||
| Trading As | LEXG (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 2/9/00 |
| Domestic Shares Offered | 10,000,000 | Offer Date | 4/6/00 |
| Foreign Shares Offered | 0 | Filing Range | $22.00 - $24.00 |
| Company Shares | 10,000,000 | Offer Price | $22.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.540 |
| Gross Proceeds | $220,000,000 | Selling | $0.920 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 47,515,051 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| J.P. Morgan & Co. | Lead Manager | (212) 648-0517 |
| CS First Boston | Co-manager | (212) 325-2000 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Punk, Ziegel & Knoell | Co-manager | (212) 308-9494 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | 0.000 | 0.306 | 0.968 | 2.242 | 4.738 | - | - |
| Income from Oper. | -0.681 | -2.867 | -5.476 | -8.192 | -12.821 | - | - |
| Net Income | -0.672 | -2.879 | -5.402 | -7.481 | -12.475 | - | - |
| E.P.S | -0.070 | -0.170 | -0.230 | -0.320 | -0.530 | - | - |
| Revenue Growth (%) | - | 216.34 | 131.61 | 111.329 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -9.61 | - | - | ||||
| Cash Flow - Inv. | 5.17 | - | - | ||||
| Cash Flow - Fin. | 3.45 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 22.29 | Current Assets | 12.62 | Current Ratio | 1.19 |
| Total Liab. | 44.23 | Current Liab. | 10.60 | Debt Ratio | 198.39% |
| Total Equity | -21.94 | Working Cap. | 2.02 | Debt to Equity Ratio | - |
| Cash | 2.03 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to increase functional genomic research efforts; expand the Human Gene Trap database and Omnibank database and library; generate full-length gene sequence for potential drug targets and therapeutic proteins and fund working capital expenditures and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Andrews & Kurth |
| Bank's Law Firm | Cahill Gordon & Reindel |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Baylor College of Medicine | 15.90 | |
| Patricof & Co. Ventures, Inc. | 8.00 | |
| Apax Partners & Co. | 8.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||